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Background: While 20–40% of patients with hepatitis C virus (HCV) monoinfection will spon-
taneously clear the virus, less is known regarding clearance with coinfections. HCV, human
immunodeﬁciency virus (HIV), and human T-cell lymphotrophic virus 1 and 2 (HTLV-1/2)
coinfection occurs due to shared routes of transmission and is prevalent in Brazil.
Objectives: To compare the proportion of patients who have spontaneously cleared HCV in
patients with HCV monoinfection to patients coinfected by HCV/HIV, or HCV/HIV/HTLV-1.
Methods: Using medical records from two clinics in Salvador, Brazil, including demographic
data  and serological markers of HCV, HIV and HTLV-I/II, cross-sectional data was obtained
from 197 patients. Patients who were anti-HCV positive and HCV RNA negative, and who
did  not receive HCV treatment were deﬁned as having cleared infection.
Results: Nineteen patients (9.5%) showed evidence of spontaneous HCV clearance; with
clearance in 9 of 108 (8.3%) patients in the HCV monoinfected group, 5 of 68 (7.4%) patients
with  HCV/HIV, and 5 of 21 (23.8%) patients with HCV/HIV/HTLV. Demographic data were not
associated with HCV clearance status. Patients coinfected with both HIV and HTLV-1 had
increased odds (5.50; 95% CI 1.00, 30.17) of spontaneous clearance of HCV compared with
patients who were HIV negative or of unknown HIV status.
Conclusion: Our study found that patients coinfected with HIV and HTLV-1 were more  likely
to  spontaneously clear hepatitis C virus than patients with HIV/HCV or HCV alone. Theeffects of HTLV coinfection on the immune response of such patients may be associatedwith these ﬁndings.
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ackground
he World Health Organization estimates that 180 million
eople, or 3% of the world’s population, are infected with hep-
titis C virus (HCV) and that 130–170 million have chronic
nfection.1,2 HCV is tropic for hepatocytes and is a signiﬁ-
ant cause of morbidity, including cirrhosis and hepatocellular
arcinoma, and mortality globally.3 HCV is a blood-borne
athogen, often in coinfection with other blood-borne infec-
ions, including human immunodeﬁciency virus (HIV) and
uman T-cell lymphotrophic virus-1/2 (HTLV-1/2). This is likely
ue to shared routes of transmission, such injection drug use
IDU), and in some contexts, contaminated blood products.4,5
Spontaneous resolution of HCV is of both scientiﬁc and
linical interest as knowledge of the time-course and factors
ssociated can inform clinical care and prevention tech-
ologies, such as vaccine development. There is consistent
vidence that about one quarter (25%) of HCV mono-infected
ndividuals spontaneously resolve HCV infection.6,7 Several
actors have been shown to be associated with spontaneous
CV clearance, including female sex, non-African ethnicity,
aundice at presentation, HLA type II alleles, and genetic
actors, most strongly, IL28B allele variants.6–11 Prospective
tudies in acutely infected patients have shown that clearance
f HCV infection is associated with a strong and broad host
mmune T-cell response.12–16
Little is known about frequency of spontaneous clearance
nd disease progression in individuals with triple infection:
CV, HIV and HTLV. HCV clearance in patients coinfected with
IV has been shown to be markedly reduced, with only 10–20%
pontaneous clearing.17–19 Furthermore, HIV/HCV coinfected
atients have signiﬁcantly higher HCV viremia levels than in
onoinfected patients and reduced response to anti-retroviral
herapy.20,21 Much  less is known about the natural history
f HCV infection in the context of HTLV. HTLV-1 infection
an cause adult T-cell leukemia/lymphoma (ATLL), which is
 proliferation of CD4+ T-cells, and Th1 activation which is
ssociated with neurological disease.22 HTLV replicates within
-cells and thereby compromises the cell-mediated immune
esponse that may inﬂuence HCV clearance.23 Three stud-
es of HCV/HTLV-1 coinfection, all of which were conducted
n groups too small to demonstrate differences, have shown
nconsistent results with respect to HCV clearance.24–26 Stud-
es in Japan have found that HCV/HTLV-1 coinfected patients
ave, on average, increased HCV viremia,25 which is consistent
ith another study showing that coinfection had a multiplica-
ive effect on the development of liver disease.27 In a recent
tudy of patients infected with HCV/HIV/HTLV-1/2 in Brazil,
e  found that those with triple infection had on average lower
LT levels than patients coinfected with HIV/HCV, suggesting
ower hepatic inﬂammation in the former group.28
Northeastern Brazil is a good location to study coinfec-
ion with these three viruses as HTLV-1 and HCV are endemic
ith a large population of asymptomatic carriers.29,30 HCV
as been estimated to infect 1.1% of Brazilians.4 In the gen-
ral population in Salvador, the prevalence of HTLV-1 and HIV
s estimated at 1.35% and 0.55%, respectively.29,31 Data from
ery select populations in Brazil, including IDU, have found
igh infection rates for HCV, HTLV-1 and HIV: 70%, 22% and5;1 9(5):486–491 487
44%, respectively.31,32 In this region, 80% of the population is
of African descent,33 providing unique population in which to
study spontaneous clearance, particularly as several studies
have shown that black and racially diverse populations have
lower HCV clearance rates.9,25,34
Objectives
To address the paucity of data on the impact of co-infection
and triple infection with HCV, HIV and HTLV, we  conducted a
cross-sectional chart review. We  compared the rates of HCV
clearance in a cohort of mono- and co-infected patients with
HCV, HCV/HIV and HCV/HIV/HTLV from two referral centers
in Salvador, Brazil.
Study  design
Study  population
Cross-sectional data were abstracted from medical charts of
patients infected with HCV, HIV/HCV, and HIV/HTLV/HCV in
two outpatients services in Salvador, Bahia, Brazil: Hospital
Universitario Professor Edgard Santos of Federal University of
Bahia (HUPES) and Centro Estadual de Diagnostico, Assisten-
cia e Pesquisa (CEDAP), the central HIV/AIDS Referral Center
in the state of Bahia. HUPES and CEDAP are both public
institutions that serve patients infected with HIV and viral
hepatitis in Bahia. Both CEDAP and the infectious disease out-
patient clinic at HUPES see approximately 10,000 patients a
year. Patients from CEDAP were primarily coinfected with HIV
(including those with HCV, or triply infected with HCV, HIV and
HTLV-1). HUPES patients were primarily HCV mono-infected,
or HCV/HTLV coinfected.
Data  collection
Patients’ records from 2008 to 2010 were reviewed; all patients
who were anti-HCV positive and aged 18 or older were
included. Sociodemographic data collected included age, sex,
race, and where medical care was received. Age was cat-
egorized by ﬁve-year intervals. Race categories were those
used in the medical charts, either white, meaning of Cau-
casian descent, black, of African descent, or “pardo”, racially
mixed descent. All data were abstracted twice by different
research assistants, and then double entered into an EPIinfo
3.5.4 database (CDC, GA, USA). Patients were grouped as anti-
HIV negative or unknown, anti-HIV positive and anti-HTLV
negative or unknown and, ﬁnally, anti-HIV positive and anti-
HTLV positive.
Laboratory  tests
Laboratory tests results were obtained from medical records,
including anti-HCV and HCV RNA, as well as HIV and HTLV
results. The majority of laboratory testing was conducted in
laboratories at the respective clinic or hospital where patients
were seen. In brief, testing was done as follows: anti-HCV
was tested for using enzyme immunoassay (EIA) (different
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Table 1 – Demographic characteristics of HCV-positive participants overall and by HIV and HTLV status at two hospitals
in Salvador, Brazil.
Prevalence (characteristic) Prevalence of infection status by characteristic
Overall Anti-HIV (−)/unknown Anti-HIV (+) and
Anti-HTLV (−)/unknown
Anti-HTLV (+),
Anti-HIV (+)
p-Valuea
N (%) N (%) N (%) N (%)
Overall 197 (100) 108 (54.8) 68 (34.5) 21 (10.7)
Site
CEDAP 82 (41.6) 4 (4.8) 61 (74.4) 17 (20.7) <0.01
HUPES 115 (58.4) 104 (90.4) 7 (6.1) 4 (3.48)
Age
40 and under 42 (21.8) 16 (38.1) 22 (52.4) 4 (9.5) <0.01
41–45 years 29 (15.0) 11 (37.9) 12 (41.3) 6 (20.7)
46–50 years 48 (24.9) 19 (39.6) 21 (43.8) 8 (16.7)
51+ years 74 (38.4) 58 (78.4) 13 (17.6) 3 (4.1)
Sex
Female 80 (40.6) 46 (57.5) 25(31.3) 9 (11.3) 0.73
Male 117 (59.4) 62 (53.0) 43(36.8) 12  (10.3)
Race
White 16 (8.1) 15 (93.8) 1(6.3) 0 (0) <0.01
Pardo (Mixed) 37 (18.8) 29 (78.4) 5(13.6) 3 (18.6)
Black 16 (8.2) 13 (81.3) 3(18.8) 0 (0)
Missing 128 (65.0) 51 (39.8) 59(46.1) 18 (14.1)a Fischer’s Exact test include missing data.
manufacturers, but most commonly Elisa Meia Axsym tests
(Abbott ELISA Kit, USA); HIV testing was determined using
two enzyme immunoassays (EIA) (HIV-1 QT, Bio Manguinhos,
Rapid Check HIV 1 and 2) and conﬁrmed by western blot
(Genelabs, Singapore). HTLV-1 was tested by EIA (Abbott
Biomerix Kit; USA), and conﬁrmed by western blot (Genelabs,
Singapore). HCV RNA was tested for using HCV Amplicor
2.0; Roche Diagnostics, Pleasenton, CA) with lower limit of
detection of 50 UI/mL (120 cp/mL). Results negative for HCV
RNA were classiﬁed as being aviremic.
Statistical  analyses
The main outcome variable of our study was HCV clearance.
Patients who  were anti-HCV positive and HCV RNA negative,
and with no record of HCV treatment were classiﬁed as hav-
ing spontaneously cleared HCV. Patients who were HCV RNA
positive or who received treatment were categorized as hav-
ing HCV infection. Covariates of interest were co-infection
with HIV and/or HTLV-1. Participants were divided into three
groups: patients with negative or unknown HIV status and
negative or unknown HTLV status (Group 1), patients with pos-
itive HIV status and negative or unknown HTLV status (Group
2) and, ﬁnally, patients with positive HIV and HTLV-1 status
(Group 3). There were no patients with positive HTLV sta-
tus whose HIV status was unknown. Univariate associations
between groups by sociodemographic and clinical factors were
assessed using Fisher’s exact tests. Firth’s logistic regression
was used to assess factors independently associated with HCV
clearance by coinfection status, adjusting for potential con-
founders including age, site and sex. Odds ratios (OR), adjusted
odds ratios (AOR) and 95% conﬁdence intervals (CI), were esti-
mated. Race was excluded from multivariate analyses due tothe signiﬁcant amount of missing data and large number of
participants who were classiﬁed as mixed race. All analyses
were conducted using STATA for Mac statistic software pack-
age version 11.0 and the Firth logit module with distribution
date: 2008/07/14.
Ethical  review
The study protocol was reviewed and approved by the
Research Ethics Committee of the Secretary of Health of the
State of Bahia (Comite de Etica em Pesquisa da Secretaria
de Saude do Estado da Bahia – CEP SESAB) and the UCSF
Committee on Human Research. Informed consent for this
retrospective chart review was waived.
Results
The study team screened 575 patients for inclusion in the
study; 357 participants were excluded because they were
not anti-HCV positive. Medical charts from 218 patients
were reviewed, of which 21 were excluded due to missing
HCV RNA status, leaving 197 records for analyses. Over half
of the patients (n = 115, 58.4%) received care at HUPES, the
remaining at CEDAP. The majority of patients were male
(n = 117 or 59.4%); mean age was 48.5 years (SD 9.67). Informa-
tion on race/ethnicity was available for 69 patients, among
those, 23.2% were White, 53.6% as “Pardo” and 23.2% as
Black (Table 1). Overall, 9.5% (n = 19) patients had evidence
of spontaneous HCV clearance. There were signiﬁcant dif-
ferences between the HIV/HTLV groupings by clinical site,
principally since the infectious disease clinic at HUPES saw
few HIV infected patients. HCV monoinfected patients were
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Table 2 – Bivariate and multivariate associations of HIV/HTLV co-infection status and demographic characteristics with
spontaneous HCV clearance in patients at two hospitals in Salvador, Brazil.
HCV spontaneous clearance
n/N (col%)
OR  (95% CI) p-Value Adjusted ORa (95% CI) p-Value
Coinfection status
HIV−/unknown 9/108 (8.3) 1 1
HIV+ and HTLV−/unknown 5/68 (7.4) 0.91 (0.30, 2.71) 0.86 1.61 (0.29, 8.97) 0.58
HIV+ and HTLV+ 5/21 (23.8) 3.49 (1.08, 11.27) 0.037 5.50 (1.00, 30.17) 0.049
HIV
Negative 2/44 (4.6) 1
Positive 10/89 (11.2) 2.25 (0.54, 9.37) 0.27
Unknown 7/64 (10.9) 2.22 (0.50, 9.79) 0.29
HTLV
Negative 5/76 (6.6) 1 1
Positive 5/24 (20.8) 3.67  (1.02, 13.2) 0.047 3.58 (1.00,12.90) 0.051
Unknown 9/97 (9.3) 1.40 (0.47, 4.17) 0.56 1.24 (0.22, 4.64) 0.75
Age
40 and under 4/42 (9.5) 1
41–45 years 4/29 (13.8) 1.51 (0.37, 6.12) 0.56
46–50 years 4/48 (8.3) 0.87 (0.22, 3.43) 0.84
51–80 years 6/74 (8.1) 0.81 (0.23, 2.88) 0.75
Sex
Female 9/80 (11.3) 1
Male 11/117 (8.6) 0.74 (0.29, 1.86) 0.52
Race
Branco (White) 1/16 (6.3) 1
Pardo (Mixed) 1/37 (2.7) 0.42 (0.04, 4.41) 0.47
Negro (Black) 3/16 (18.8) 2.68 (0.35, 20.75) 0.35
Missing 14/128 (10.9) 1.31 (0.22, 7.63) 0.77
Site
CEDAP 8/82 (9.7) 1
HUPES 11/115 (9.6) 0.96 (0.38, 2.46) 0.94
s
(
b
H
w
s
c
t
n
H
o
D
I
B
H
H
H
t
a
da Adjusted for: sex, age, and site using Firth’s logistic regression.
igniﬁcantly older than co-infected patients with a majority
78.4%) over age 50.
Table 2 shows unadjusted and adjusted associations
etween co-infections and demographic characteristics with
CV clearance status. HIV co-infection was not associated
ith HCV clearance. However, positive HTLV status was con-
istently associated with over three-fold higher odds of HCV
learance in a univariate and multivariate models. As well,
he proportion of HIV/HTLV-1 positive patients that sponta-
eously cleared HCV was signiﬁcantly higher compared to
IV-negative patients with adjusted odds of HCV clearance
f 5.50 (95% CI 1.00–30.17, p = 0.049).
iscussion
n this study of HCV infected patients in Salvador, Bahia,
razil, we  found that patients who  were coinfected with
TLV had greater likelihood of spontaneous clearance of
CV infection overall. Additionally, those with HIV and
TLV infection had an increased clearance: almost a quar-
er (23.9%) of patients who had evidence of HCV infection
nd who  were also coinfected with the two other viruses
emonstrated evidence of spontaneous clearance comparedto 8% of HIV-positive/HTLV-negative patients. Our results
suggest the possibility that HTLV infection may have immune
effects that enhance responses to HCV infection. In a previous
study we  showed that cultured mononuclear cells from these
HIV/HTLV coinfected patients had a higher spontaneous pro-
duction of IL-1, -interferon, and lower production of IL-4.35
In addition, in a recent work, we also detected signiﬁcantly
higher serum levels of eight proinﬂammatory cytokines
(IL-1b, IL-2, FGF, -IFN, IP-10, MIP-1 , MIP-1 , TNF-) in
patients coinfected with HIV-HCV and HTLV, in comparison
to HIV-HCV coinfected individuals.36 There was also a strong
association between higher levels of these cytokines and
sustained virological response, among patients treated for
HCV infection.36 We do not know the temporal order in which
patients were infected, however if HTLV infected patients
develop higher HCV viremia in acute infection, as suggested
by other studies,25 this could also be associated with immune
responses that increase HCV clearance.37,38 Taken together,
these results suggest that this proﬁle of immune response is
a likely result of HTLV coinfection, potentially contributing
to the higher rate of spontaneous HCV clearance seen in
patients in this study. We believe these new data can point
to new directions for immunology studies of successful
HCV infection responses. A better understanding of such
i s . 2 0
r
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1
1
1
1
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mechanisms could be translated in future improvements
on treatment for patients coinfected with HIV and
HCV.
Our study had many  limitations including a small sam-
ple size that restricted our statistical power resulting in large
conﬁdence intervals with results of nominal signiﬁcance. We
chose to use Firth logistic regression in order to adjust for
important covariates, such as sex, and due to our small sam-
ple size with separation. We  also had a signiﬁcant amount of
missing data that we  were unable to obtain from the medical
charts, particularly in regards to race, as well as coinfec-
tions. In regard to the missing data for race, the data that
was collected reﬂected the racial distribution found in other
studies conducted in the state of Bahia as well as census
data.39–41 Given the large amount of missing data and that
the majority of participants were of mixed racial background,
this variable did not add meaningful information to our mul-
tivariate model. With respect to missing coinfection data, we
conducted further sensitivity analyses examining less conser-
vative groupings assuming patients with unknown HIV status
or HTLV status were positive for HIV and HTLV. These analyses
also showed similar signiﬁcant ﬁndings: patients with HIV and
HTLV had increased odds of spontaneous clearance of HCV.
We used two different clinics to obtain our study population,
which could also have introduced selection or information
bias if clinical data was collected with systematic differences,
which we  could not assess. We  did not identify if patients were
infected with HTLV-1 or II; however HTLV-1 is present in 95%
to 98% of all infections in Salvador, so it is likely the prevalent
infection in this analysis.39 We were also not able to assess
genetic associations between interferon-lambda 3 (IFNL3, pre-
viously called IL28B), and which is known to be associated with
HCV clearance.42,43 Our sampling allowed us to capture the
majority of patients with recent HCV infections receiving care
in the state of Bahia; however, our study has inherent selection
bias as HIV infected patients received more  comprehensive
and regular testing for HCV than non-HIV infected patients.
Finally, this was a cross-sectional study using historical data,
which limits our ability to fully control for all confounders and
determine causality.
Very little has been published on the role of coinfections in
patients with HCV. Despite its limitations, our study is the ﬁrst
to examine spontaneous HCV clearance in patients infected
with HTVL and HIV, a more  complex and potentially real-
istic scenario than examining these diseases individually as
many of these infections coexist and are transmitted via simi-
lar routes. The present ﬁndings suggest that HTLV coinfection
may have a positive effect on the spontaneous clearance of
HCV, especially in HIV-1 coinfected patients. The available
research on the immune response in this population indicates
that the production of proinﬂammatory cytokines is upreg-
ulated in coinfected individuals, potentially contributing to
HCV clearance. Taken together, these results provide a new
insight on the role of speciﬁc immune response in HCV infec-
tion and advance understanding of HTLV and HCV infections.Funding
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